Starpharma Registers VIRALEZE nasal spray in Indonesia
- Starpharma (SPL) registers its nasal spray product VIRALEZE in Indonesia after gaining marketing authorisation
- The company says Indonesia represents an “exciting market opportunity” as its the largest and most populated country in Southeast Asia, and it’s now in discussions with potential distribution partners
- The VIRALEZE nasal spray is now registered in more than 30 countries and is available in pharmacies, retail outlets and online in certain markets
- The company is also continuing to progress regulatory and commercial activities in multiple other countries
- Shares in the company are up 2.86 per cent, trading at 54 cents at 1:53 pm AEDT